Braveheart Bio | $185,000,000 | (Nov 6, 2025)
CommanderAI | $5,000,000 | (Nov 6, 2025)
Procurement Sciences | $30,000,000 | (Nov 6, 2025)
Certified by Founder
Lodge
HI-Bio
start up
United States
- South San Francisco, California
- 05/01/2024
- Series B
- $95,000,000
Human Immunology Biosciences (HI-Bio) is leading clinical immunology into its next chapter with therapies that target cellular drivers of disease. HI-Bio uses a precision medicine approach to deliver therapies for patients with the auto-immune, allergic and inflammatory diseases that can together be referred to as immune-mediated diseases (IMDs).
- Industry Biotechnology Research
- Website https://hibio.com/
- LinkedIn https://www.linkedin.com/company/hibio/about/
Freeda | $3,912,210 | (Nov 6, 2025)
NEOK Bio | $75,000,000 | (Nov 6, 2025)
LambdaVision, Inc. | $7,000,000 | (Nov 6, 2025)
Flux XII Inc. | $3,950,000 | (Nov 6, 2025)
Boostie | $500,000 | (Nov 6, 2025)
Rilevera | $3,000,000 | (Nov 6, 2025)
Wisconsin Alumni Research Foundation (WARF) | $3,950,000 | (Nov 6, 2025)
Cactus | $7,000,000 | (Nov 6, 2025)
GitLaw | $30,000,000 | (Nov 6, 2025)